Compare Tango Therapeutics Inc. (TNGX) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Waste Management, Inc. — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B), while Waste Management, Inc. trades at $217.51 (market cap $86.24B). The key difference: Waste Management, Inc. is far larger — about 23.1× Tango Therapeutics Inc.'s market cap, and Waste Management, Inc. pays a 1.75% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Waste Management, Inc. for 131 Days on average.
| TNGX | WM | |
|---|---|---|
Market Cap | $3.74B | $86.24B |
Volume | 3,438,781 | 1,938,815 |
Sector | Health | Industrials |
52-Week High | $32.90 | $246.51 |
52-Week Low | $7.50 | $196.77 |
Typical Hold Time | 0 Days | 131 Days |
Enterprise Value | $2.76B | $109.04B |
Dividend Yield | — | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Waste Management (WM) trades at $211.83, up 0.33% with a bullish technical signal despite mixed moving averages. The company demonstrates strong fundamentals with $25.2B revenue, 11.12% net margin, and robust cash flow generation. Recent earnings show two beats out of three quarters, with Q3 2026 results pending. Analyst consensus is strongly positive with 54% buy ratings and no sell recommendations.
WM presents a compelling investment case with consistent revenue growth, strong profitability metrics, and defensive business model. However, elevated valuation multiples (P/E 29.96) and rising debt levels warrant caution. The stock offers stability through economic cycles but faces margin pressure from cost inflation and competitive threats in waste management services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
